Research Topics
| Allan GibofskySummaryAffiliation: Hospital for Special Surgery Country: USA Publications
|
Detail Information
Publications
Rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study: safety and etanercept utilization analyses from the RADIUS 1 and RADIUS 2 registriesAllan Gibofsky
Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
J Rheumatol 38:21-8. 2011....
Comparative effectiveness of current treatments for rheumatoid arthritisAllan Gibofsky
Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
Am J Manag Care 18:S303-14. 2012....
Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritisAllan Gibofsky
Weill Medical College of Cornell University, Hospital for Special Surgery, New York, NY, USA
Am J Manag Care 18:S295-302. 2012....
American College of RheumatologyAllan Gibofsky
Hospital for Special Surgery, New York, New York, USA
J Med Assoc Ga 91:35-6. 2002
Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled studyAllan Gibofsky
Department of Medicine and Public Health, Weill Medical College of Cornell University, Hospital for Special Surgery, New York, New York 10021, USA
Clin Ther 29:1071-85. 2007..This study compared the efficacy and tolerability of the cyclooxygenase-2-selective inhibitor valdecoxib with the nonselective NSAID naproxen and with placebo in treating severe rheumatoid arthritis (RA)...
Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) studyAllan Gibofsky
Department of Rheumatology, Hospital for Special Surgery, New York, NY, USA
Curr Med Res Opin 22:169-83. 2006..RADIUS provides a snapshot of use patterns, effectiveness, and safety of DMARDs, biologics, and combination therapies used to manage RA in clinical practice...
An analysis of recent antitrust issues affecting specialty practice: is dermatology immune?Allan Gibofsky
Weill Medical College of Cornell University, New York, NY, USA
Semin Cutan Med Surg 24:137-43. 2005..Although recent case law has involved actions undertaken by physicians in other specialties of Medicine (e.g. oncology) the activities reviewed will likely be applicable to Dermatologists as well...
Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trialAllan Gibofsky
Hospital for Special Surgery Weill Medical College of Cornell University, New York, New York 10021, USA
Arthritis Rheum 48:3102-11. 2003..To compare the efficacy of the cyclooxygenase 2 (COX-2)-specific inhibitors celecoxib and rofecoxib in treating the signs and symptoms of osteoarthritis (OA)...
Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJoseph A Markenson
Hospital for Special Surgery, New York, NY 10021, USA
J Rheumatol 38:1273-81. 2011..To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA)...
The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritisCarla R Scanzello
Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Curr Rheumatol Rep 10:49-56. 2008..This review highlights the evidence behind the effectiveness of other, non-NSAID pharmacologic options in the treatment of pain and inflammation in osteoarthritis...
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryJeffrey D Greenberg
New York University Hospital for Joint Diseases, Department of Rheumatology, 301 East 17th Street, Suite 1410, New York, NY 10003, USA
Ann Rheum Dis 71:1134-42. 2012..To compare the effectiveness of anti-tumour necrosis factor (TNF) agents in biologically naive and 'switched' rheumatoid arthritis (RA) patients...
Clinical profiles of celecoxib and rofecoxib in the rheumatic diseasesAllan Gibofsky
Weill Medical College of Cornell University, New York, New York, USA
J Hypertens Suppl 20:S25-30. 2002..This presentation reviews the mechanism of action of these agents, the clinical studies showing their effectiveness for treatment of arthritis, and the gastrointestinal side effect profiles compared with conventional NSAIDs...
Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis CTimothy B Niewold
Hospital for Special Surgery, New York, NY, USA
Arthritis Rheum 54:2335-7. 2006
Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesicAllan Gibofsky
Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Am J Ther 15:241-55. 2008..The purpose of this review is to highlight the efficacy and safety of extended-release opioid analgesics utilized in the management plan of chronic pain due to osteoarthritis...
If I am not for myself, who will be for me?Allan Gibofsky
Weill Medical College of Cornell University and Hospital for Special Surgery, New York, New York, USA
Arthritis Rheum 48:869-72. 2003
Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?Ora Singer
Department of Rheumatology, Medical College of Georgia, Augusta, Georgia, USA
Curr Opin Rheumatol 23:288-92. 2011..To review the recent efficacy and safety data comparing methotrexate (MTX) and leflunomide (LEF) monotherapy, in combination with biologic therapies and in combination with each other...
The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritisCarla R Scanzello
Division of Rheumatology, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA
Curr Pain Headache Rep 11:415-22. 2007..This review highlights the evidence behind the effectiveness of other, non-NSAID pharmacologic options in the treatment of pain and inflammation in osteoarthritis...
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registryArthur L Weaver
University of Nebraska Medical Center, Omaha, NE, USA
Curr Med Res Opin 22:185-98. 2006..To evaluate the effectiveness of select biologics, methotrexate (MTX), and other disease-modifying anti-rheumatic drugs (DMARDs) in the management of adult rheumatoid arthritis (RA) in routine clinical practice...
The role of drug and disease registries in rheumatic disease epidemiologyJoel M Kremer
Albany Medical College, 1367 Washington Avenue, Albany, NY 12206, USA
Curr Opin Rheumatol 20:123-30. 2008..This review highlights the present state of efforts at registry implementation which exist internationally. These efforts are contrasted with those in the USA...
Pay for performance in rheumatology: will we get the carrot or the stick?Allan Gibofsky
Arthritis Rheum 59:1203-6. 2008
Improving survival in inflammatory rheumatic diseases: a neglected goal?Theodore Pincus
Division of Rheumatology and Immunology, Vanderbilt University School of Medicine, 203 Oxford House, Box 5, Nashville, TN 37232 4500, USA
Curr Rheumatol Rep 8:401-3. 2006
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologistsTheodore Pincus
Arthritis Rheum 46:851-4. 2002
